Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of meningococcal serogroup B rLP2086 vaccine in healthy adolescents
2008-007789-51Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B recombinant lipoprotein 2086 vaccine in meningococcal disease (4 arms), sponsored by Pfizer. Primary endpoint: Seroconversion rate by serum bactericidal assay after dose 2 and dose 3. Started Feb 2009; status: completed.
02
Drugs
meningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2008-007789-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007789-51.